What does JP — revenue mean?

The total revenue earned from customers located in Japan, excluding taxes.

How do you interpret JP — revenue?

An increase indicates growing market demand or successful commercial execution in Japan, while a decrease may signal competitive pressure, regulatory hurdles, or declining product adoption in that region.

How does JP — revenue compare across companies?

Comparable to regional revenue disclosures in other biopharmaceutical companies, often benchmarked against total international revenue or specific major market performance.

Cytokinetics CYTK JP — Revenue

Discontinued — last reported Q4 '17

Similar metrics at other companies

RVTYJAPAN — Revenue from Contract with Customer, Excluding Assessed Tax

$22.12M+7.3%

SNPSJP — Revenue

$77.82M+18.4%

AEISJP — Revenue

$51.2M+207%

LSCCJP — Revenue

$2.35M-81.9%

ONTOJP — Revenue

$16.88M+102%

PLJP — Revenue

$9.5M—

Other financials

Income statement

See full

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

See full

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

See full

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

See full

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

See full

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

See full

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Cytokinetics’s 10-Q, filed November 9, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does JP — revenue mean?: The total revenue earned from customers located in Japan, excluding taxes.
How do you interpret JP — revenue?: An increase indicates growing market demand or successful commercial execution in Japan, while a decrease may signal competitive pressure, regulatory hurdles, or declining product adoption in that region.
How does JP — revenue compare across companies?: Comparable to regional revenue disclosures in other biopharmaceutical companies, often benchmarked against total international revenue or specific major market performance.